Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples